Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433449 | 1.00 | USP30 (0.54) | USP30MEN1KMT2AHTTGABRA5 | |
| SCHEMBL20986825 | 0.88 | USP30 (0.54) | USP30MEN1KMT2AHTTGABRA5 | |
| SCHEMBL20986823 | 0.88 | USP30 (0.54) | USP30MEN1KMT2AHTTGABRA5 | |
| SCHEMBL7016338 | 0.88 | L3MBTL1 (0.53) | MEN1KMT2AHTTL3MBTL1GPR119 | |
| SCHEMBL10226748 | 0.86 | USP30 (0.60) | USP30GABRA5HTR6BCHEJAK2 | |
| SCHEMBL16163467 | 0.86 | USP30 (0.60) | USP30GABRA5HTR6BCHEJAK2 | |
| SCHEMBL2728420 | 0.86 | USP30 (0.60) | USP30GABRA5HTR6BCHEJAK2 | |
| SCHEMBL7304645 | 0.85 | ITGB3 (0.60) | USP30MEN1KMT2AHTTSTS | |
| SCHEMBL3710438 | 0.84 | USP30 (0.50) | USP30MEN1KMT2AHTTITGB3 | |
| SCHEMBL3313424 | 0.84 | USP30 (0.63) | USP30KMT2AGABRA5L3MBTL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | USP30 1960/4885MEN1 2770/4885KMT2A 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.